Seema S. Aceves, MD, PhD - Living With Eosinophilic Esophagitis: Recognizing the Burden on Patients and Integrating Targeted Therapy to Improve Outcomes
Go online to PeerView.com/BJF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease that is triggered by food and/or environmental allergens. It is characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. EoE affects about 1 in 2,000 people in the United States, and its prevalence is increasing. Until recently, there were no FDA-approved therapies, and management was limited to dietary approaches, drugs such as proton pump inhibitors and topical corticosteroids, and esophageal dilation. Targeted biologic therapies, some of which are already approved for other type 2 inflammatory disorders, are now available or are in development for the treatment of EoE. A recent PeerView live event helped to prepare clinicians to appropriately use these agents and offered a patient perspective on disease burden, the disconnect between symptoms and disease activity, and the need for continuous monitoring and maintenance treatment. The expert faculty offered recommendations for pediatric patient populations and told the “Story Behind the Science,” adding meaning to the data. If you couldn’t attend the live event, check out this on-demand version now! Upon completion of this activity, participants should be better able to: Discuss the burden of eosinophilic esophagitis (EoE) on patient/caregiver quality of life, the progressive nature of the disease, and the need for continuous monitoring and treatment, thereby improving the standard of care; Recognize the role of underlying type 2 inflammation in the development and progression of EoE and describe the rationale for targeted treatment, particularly when type 2 comorbidities are present; and Employ the latest expert recommendations and clinical evidence to treat patients with EoE, including pediatric populations, using a shared decision-making approach.